

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Yoshihiro URADE et al. : **Mail Stop: PCT**
Serial No. NEW : Attorney Docket No. 2005_0021A
Filed January 11, 2005 :

DRUGS FOR IMPROVING THE PROGNOSIS OF
BRAIN INJURY AND A METHOD OF SCREENING
THE SAME

[Corresponding to PCT/JP03/08904 Filed July 14, 2003]

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the reference listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- ☐ each U.S. Patent and U.S. Patent application publication;
- ☒ each reference previously cited in the international application PCT/JP03/08904; and/or
- ☐ each reference previously cited in prior parent application Serial No. _____.

1a. ☒ This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, **or**

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. ☐ This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

(1) ☐ the certification of paragraph 2 below is provided, **or**

(2) ☐ the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

1c. ☐ This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. ☐ that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3. ☐ Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.

4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. ☐ a full or partial English language translation submitted herewith,
 - b. ☒ a foreign patent office search report (in the English language) submitted herewith,
 - c. ☐ the concise explanation contained in the specification of the present application at page,
 - d. ☐ the concise explanation set forth in the attached English language abstract,
 - e. ☐ the concise explanation set forth below or on a separate sheet attached to the reference:

5. ☒ A foreign patent office search report citing one or more of the references is enclosed.

Respectfully submitted,

Yoshihiro URADE et al.

By Warren M. Cheek, Jr.
 Warren M. Cheek, Jr.
 Registration No. 33,367
 Attorney for Applicants

WMC/dlk
 Washington, D.C. 20006-1021
 Telephone (202) 721-8200
 Facsimile (202) 721-8250
 January 11, 2005

Sheet 1 of 1

INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

ATTY DOCKET NO.
2005_0021A

SERIAL NO.
NEW

10/520781

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

LIST OF REFERENCES CITED BY APPLICANT(S)
(Use several sheets if necessary)

Date Submitted to PTO: January 11, 2005

APPLICANT
Yoshihiro URADE et al.

FILING DATE
January 11, 2005

GROUP

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	AE	2001-220354	8/2001	JP				
	AF	1186303	3/2002	EP				
	AG	01/14377	6/2001	WO				
	AH	97/44031	11/1997	WO				
	AI	11-116477	4/1999	JP				
	AJ	00/53573	9/2000	WO				
	AK	2001-103869	4/2001	JP				
	AL	01/24627	4/2001	WO				
	AM							

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AN	N. Matsushita, "Prostaglandin D Gosei Koso Sogaiyaku Allergy-sei Zensoku Chiryoyaku to Shite no Kanosei", Protein, Nucleic Acid and Enzyme, Vol. 45, No. 6, 2000, pp. 1072-1076.
	AO	Yu J. Liu et al., " Effects of BW A868C, a selective prostaglandin DP receptor antagonist, in dog isolated vascular preparations", European Journal of Pharmacology, Vol. 303, No. 3, 1996, pp. 187-192.
	AP	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of form with next communication to applicant.